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 2 
Abstract 26 
 27 
Multi-targeting antibiotics, i.e., single compounds capable of inhibiting two or more bacterial targets 28 
are generally considered as a promising therapeutic strategy against resistance evolution. The 29 
rationale for this theory is that multi-targeting antibiotics demand the simultaneous acquisition of 30 
multiple mutations at their respective target genes to achieve significant resistance. The theory 31 
presumes that individual mutations provide little or no benefit to the bacterial host. Here we propose 32 
that such individual, stepping-stone mutations can be prevalent in clinical bacterial isolates, as they 33 
provide significant resistance to other antimicrobial agents. To test this possibility, we focused on 34 
gepotidacin, an antibiotic candidate that selectively inhibits both bacterial DNA gyrase and 35 
topoisomerase IV. In a susceptible organism, Klebsiella pneumoniae, a combination of two specific 36 
mutations in these target proteins provide an over 2000-fold reduction in susceptibility, while 37 
individually none of these mutations affect resistance significantly. Alarmingly, strains with decreased 38 
susceptibility against gepotidacin are found to be as virulent as the wild-type Klebsiella pneumoniae 39 
strain in a murine model. Moreover, numerous pathogenic isolates carry mutations which could 40 
promote the evolution of clinically significant reduction of susceptibility against gepotidacin in the 41 
future. As might be expected, prolonged exposure to ciprofloxacin, a clinically widely employed 42 
gyrase inhibitor, co-selected for reduced susceptibility against gepotidacin. We conclude that 43 
extensive antibiotic usage could select for mutations that serve as stepping-stones towards resistance 44 
against antimicrobial compounds still under development. Our research indicates that even balanced 45 
multi-targeting antibiotics are prone to resistance evolution.  46 
 47 
  48 
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 3 
Introduction 49 
Antibiotic discovery has been driven by the need for new therapeutics that are not subject to rapid 50 
resistance development. Due to the rise of drug-resistant bacteria, the commercial success of 51 
antibiotic development is unpredictable(1, 2). Antibiotic combination therapy has long been suggested 52 
as a potential strategy to delay resistance evolution(3, 4). The rationale for this theory is that drugs 53 
with different modes of action generally require different mutations in respective target genes to 54 
achieve resistance, and the simultaneous acquisition of multiple specific mutations is exceedingly 55 
rare. Although successful in many cases, antimicrobial combination therapy suffers from several 56 
limitations(5, 6). Multi-target antibiotic strategy is an emerging alternative. There are multiple 57 
mechanisms by which antimicrobial compounds may inhibit multiple bacterial targets. In the case of 58 
hybrid drugs, two antibiotic pharmacophores with dissimilar targets are covalently linked to form one 59 
molecule. Other antibiotic compounds equipotently target two or more homologous proteins. Indeed, 60 
resistance to linezolid has typically been associated with multiple mutations in varying numbers of 61 
copies of the genes encoding 23S ribosomal RNA, all of which have limited effects on resistance 62 
individually (7). Finally, they may target multiple, non-overlapping regions of a single bacterial protein. 63 
Currently, designing multi-target antibiotics is a major focus of the pharmaceutical industry, but until 64 
now relatively few drugs have been demonstrated to achieve a balanced inhibition of multiple 65 
microbial targets. (8–10) Due to the shortage of in-depth resistance studies, our knowledge on the 66 
tempo and mode of resistance development against multi-target antibiotics remains limited (but 67 
see(11–13)). 68 
 Gepotidacin (GSK2140944) is an exemplary candidate to study resistance evolution towards 69 
multi-targeting antibiotics (Figure 1A). Gepotidacin is a novel triazaacenaphthylene antibiotic 70 
candidate currently in phase 2b clinical trials(14, 15) and is expected to enter the clinical practice in 71 
the upcoming years(16, 17). The molecule inhibits bacterial DNA gyrase and topoisomerase IV with a 72 
novel mode of action. Using a standard frequency-of-resistance test recent studies have failed to 73 
identify resistant clones of Neisseria gonorrhoeae and Escherichia coli against this new compound(8, 74 
18), suggesting that individual mutations cannot provide substantial resistance to gepotidacin. It is 75 
especially active against Gram-negative pathogens, such as Klebsiella pneumoniae. According to the 76 
WHO, infections caused by multi-drug resistant Klebsiella strains are emerging as a top-ranked 77 
challenge in the health-care sector(19). In this work, we demonstrate that contrary to expectations, 78 
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 4 
reduced susceptibility to gepotidacin evolves rapidly in K. pneumoniae, which has potential 79 
implications for the future clinical use of this new antibiotic candidate. 80 
 81 
Results 82 
 83 
Molecular modelling with directed evolution accurately predicts the positions and impact of 84 
resistance mutations 85 
Prior studies have demonstrated that gepotidacin selectively inhibits both bacterial DNA gyrase and 86 
topoisomerase IV by a unique mechanism(8, 16), but the exact molecular mechanisms of inhibition 87 
have not been thoroughly characterized. Therefore, we first sought to study the exact molecular 88 
interactions between gepotidacin and Escherichia coli’s DNA gyrase and topoisomerase IV protein 89 
complexes, using molecular modelling (Materials and Methods and Supplementary Note 1). Molecular 90 
dynamics simulations capture the atomic interactions between the drug and the target protein in time 91 
(Supplementary Figure S1). The analysis has revealed that D82 in the GyrA subunit of DNA gyrase 92 
and the homologous position, D79 of the ParC subunit of topoisomerase IV form an intermolecular 93 
salt bridge with gepotidacin (Figure 1B and C, Supplementary Note 2, and Supplementary Figure S1 94 
and S2). Therefore, mutations at these binding sites are expected to provide reduced susceptibility to 95 
gepotidacin, and it was indeed so (see below).  96 
Previously we subjected the potential target genes to a single round of DIvERGE 97 
mutagenesis in E. coli, and next subjected the mutant library to gepotidacin stress, followed by 98 
sequencing the isolates with reduced susceptibility (18). As gepotidacin has not entered clinical use 99 
and thus, its clinical breakpoint is not established, we defined reduced susceptibility to gepotidacin as 100 
the MIC value that is equal or higher than the peak plasma concentration of the drug (9 g/ml, (14)). 101 
In our current work, the analysis has been repeated in K. pneumoniae using nearly identical 102 
experimental settings (Figure 1D). The results of the mutagenesis assays are qualitatively the same 103 
for the two species: D82 within the GyrA subunit and D79 of the ParC subunit are found to be mutated 104 
in all the clones isolated, and no further mutations have been found (Supplementary Table S4). 105 
Moreover, subsequent saturation mutagenesis of the two mutational hot-spots has recapitulated that 106 
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 5 
the combination of these two specific mutations (GyrA D82N, ParC D79N) is responsible for a high-107 
level of reduced susceptibility to gepotidacin (Supplementary Table S4).  108 
To understand the molecular mechanisms behind the reduced susceptibility, we have 109 
computationally modelled the molecular interactions between gepotidacin and asparagine mutants at 110 
GyrA D82 and ParC D79 positions using molecular dynamics simulations and the Molecular 111 
Mechanics/Generalized Born Surface Area (MM-GBSA)(20) method. MM-GBSA has predicted that 112 
the observed mutations (GyrA D82N and ParC D79N) weaken the interaction between the target 113 
proteins and gepotidacin. (Supplementary Figure S1.).  Thus, the combination of DIvERGE 114 
mutagenesis assays and molecular dynamics simulations have revealed the putative binding sites for 115 
gepotidacin in DNA gyrase and topoisomerase IV protein complexes. Furthermore, the disruption of 116 
an indispensable salt bridge between the drug and its two binding sites resulted in high-level 117 
reduction of susceptibility in K. pneumoniae. 118 
 119 
Exceptionally strong synergism between mutations associated with reduced susceptibility 120 
Next, we have studied the individual, as well as the combined effects of these mutations on 121 
susceptibility. For this purpose, the mutations were inserted individually into the genomes of E. coli K-122 
12 MG1655 and K. pneumoniae ATCC 10031. The double-mutants were found to display an over 123 
560- and a 2080-fold reduction in gepotidacin susceptibility level compared to the corresponding wild-124 
type strains of E. coli and K. pneumoniae, respectively (Table 1, see also ref (21)). In contrast, the 125 
single-mutants were found to show no considerable changes in gepotidacin susceptibility in both 126 
species (Table 1). These findings are consistent with prior single-step resistance selection studies 127 
that failed to recover mutants with significant resistance(8, 18).  128 
 129 
Fitness cost of decreased gepotidacin susceptibility is limited  130 
Antibiotic resistance typically induces a fitness cost in the form of reduced bacterial growth rates(22), 131 
and such costs shape the long-term stability of antibiotic-resistant populations(23–25). Thus, we have 132 
investigated the fitness effects of target-mediated reduction of susceptibility to gepotidacin in K. 133 
pneumoniae. For this aim we have studied the wild-type and mutant K. pneumoniae strains, the latter 134 
carrying mutations associated with reduced susceptibility to gepotidacin or fluoroquinolones.  135 
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 6 
The fluoroquinolone resistance-causing mutations in point are widespread in clinical isolates(26–28) 136 
and affect the same genes (namely, gyrA and parC), therefore they provide a benchmark to estimate 137 
the fitness costs compared to the wild-type strain. Relative fitness was estimated by pairwise 138 
competition experiments between the wild-type strain and a specific mutant strain in nutrient-rich, 139 
antibiotic-free bacterial medium (MHBII) at 37°C. Using established protocols, we have found that the 140 
mutation combination of GyrA D82N and ParC D79N which confers reduced susceptibility to 141 
gepotidacin significantly decreases fitness in K. pneumoniae. However, the fitness cost of gepotidacin 142 
resistance-associated mutations is comparable to the fitness cost of canonical, clinically relevant 143 
fluoroquinolone resistance-causing mutations. Importantly, ParC D79N mutation is found to confer no 144 
measurable fitness cost individually (Figure 2A). Our findings remained the same when active human 145 
blood serum was added to the medium. 146 
 147 
Mutants with reduced susceptibility to gepotidacin display no changes in virulence in a murine 148 
infection model 149 
We next investigated whether mutants with reduced susceptibility to gepotidacin display reduced 150 
virulence in vivo. As drug-resistant K. pneumoniae is frequently responsible for wound and systemic 151 
infections, we have studied a murine thigh wound infection model(29, 30). Specifically, we have 152 
examined the wound colonization capacity of the wild-type strain, as well as that of representative K. 153 
pneumoniae mutants with reduced gepotidacin or ciprofloxacin susceptibility. For this purpose, the 154 
wild-type strain, as well as each isogenic mutant strain was inoculated into the thigh tissue of female 155 
ICR mice (n = 5). After 26 hours, bacterial colonization was determined by plating thigh tissue 156 
homogenates to MHBII agar plates. No significant decrease in in vivo virulence was observed for any 157 
of the mutants compared to the wild-type strain (Figure 2B). It is worth noting however that performing 158 
in vivo competition experiments in a mouse infection model would also be desirable to further 159 
characterize the in vivo virulence of the mutations causing reduced susceptibility to gepotidacin and in 160 
future work we plan to analyze that. 161 
  162 
 163 
Cross-resistance analysis between gepotidacin and ciprofloxacin  164 
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 7 
Several prior works demonstrate that certain resistance mutations are present in bacterial populations 165 
long before being exposed to an antibiotic in point. Thus, we hypothesized that prolonged use of other 166 
antibiotics might select for mutations that serve as stepping-stones towards reduced susceptibility to 167 
gepotidacin. The best candidate antibiotic family is fluoroquinolones, as they are widely employed in 168 
clinical practice, and similarly to gepotidacin, they target the gyrase/topoisomerase protein 169 
complexes, albeit with a notably different molecular mechanism(17, 31). Moreover, the putative 170 
binding sites of gepotidacin and fluoroquinolones on the GyrA protein are adjacent to each other, 171 
separated by a single amino acid only (see figure 1B, and refs (32–34)). Despite the functional 172 
similarities between these drug classes, a prior paper reported that fluoroquinolone-resistant clinical 173 
isolates displayed no cross-resistance to gepotidacin(17).To re-investigate this issue, we have 174 
focused on ciprofloxacin, a widely employed and well-characterized fluoroquinolone drug. Several 175 
ciprofloxacin-resistance conferring mutations and mutation combinations in clinical isolates provide no 176 
relevant cross-resistance against gepotidacin (Supplementary Table S5.). More surprising results 177 
have emerged by testing the effect of mutations conferring reduced susceptibility to gepotidacin on 178 
ciprofloxacin susceptibility. We have found that the GyrA D82N single-mutant strain displays an over 179 
16-fold increase in ciprofloxacin-resistance level compared to the wild-type K. pneumoniae ATCC 180 
10031 strain. This finding is even more remarkable if we consider that the same mutation confers only 181 
a twofold increase in gepotidacin MIC level. As might be expected, the GyrA D82N and ParC D79N 182 
double-mutants also display significant resistance to ciprofloxacin (Table 1).   183 
Our findings raise the possibility that the D82N mutation of GyrA might be present in 184 
fluoroquinolone-resistant clinical isolates, rendering the subsequent emergence of double-mutants 185 
with reduced susceptibility to gepotidacin feasible. We have systematically investigated the 186 
prevalence of the GyrA D82N and ParC D79N mutations in currently available sequence databases 187 
(as of 9 October 2018). Systematic sequence search has revealed that both mutations occur in a wide 188 
range of Gram-negative and Gram-positive bacteria (Supplementary Table S2 and Supplementary 189 
Figure S4, also Supplementary File 1), including fluoroquinolone-resistant clinical isolates of E. 190 
coli(35), and other species belonging to the Salmonella, the Mycoplasma, Clostridium, Citrobacter, 191 
Streptococcus, and Neisseria genera. Neisseria and Streptococcus are especially noteworthy, as 192 
infections caused by these genera are reported to be the targets of gepotidacin in recent clinical 193 
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 8 
trials(14, 15, 36). These results indicate that several clinically occurring human pathogens require 194 
only a single extra mutation to evolve highly reduced susceptibility to gepotidacin. 195 
 196 
Ciprofloxacin stress selects for reduced susceptibility to gepotidacin in the laboratory  197 
To establish further that ciprofloxacin promotes reduced susceptibility to gepotidacin, we have 198 
initiated laboratory evolution under ciprofloxacin stress with wild-type K. pneumoniae ATCC 10031, as 199 
well as the wild-type and mutS strains of E. coli K-12 MG1655. The previously established protocol 200 
aims to maximize the level of drug resistance in the evolving populations that develop in a fixed time 201 
period,(37–39) being approximately 116 generations in our case. Six parallel evolving populations of 202 
each strain were exposed to gradually increasing concentrations of ciprofloxacin. In line with previous 203 
clinical and laboratory studies(31, 40), ciprofloxacin resistance was seen to emerge quickly in our 204 
experiments (Figure 3A), especially in mutS hypermutator lineages.  Despite the short time-frame, 205 
all E. coli and K. pneumoniae populations reached ciprofloxacin-resistance levels equal to or above 206 
the EUCAST clinical breakpoint(41) (Figure 3A and 3B). Three randomly selected, ciprofloxacin 207 
resistant lineages per strain were selected for gepotidacin MIC measurements. Strikingly, all have 208 
been found to display an over 64 to 1058-fold decrease in gepotidacin susceptibility level compared to 209 
the corresponding control strains (Figure 3B). Next, we carried out of whole genome sequence 210 
analysis of 2 and 3 evolved lineages derived from E. coli K-12 MG1655 and K. pneumoniae ATCC 211 
10031, respectively. Although these lineages display markedly reduced gepotidacin susceptibilities 212 
(Figure 3B), they do not carry mutations at GyrA D82 or ParC D79, suggesting that multiple other 213 
mutations may also select for reduced susceptibility to gepotidacin. Indeed, the whole genome 214 
sequencing has revealed that these ciprofloxacin resistant lineages carry putative resistance 215 
mutations in genes involved in membrane efflux (acrR, soxR, marR) and general stress response  216 
(cusS, rpoB) (Supplementary Table S3).  Overall, these results strongly suggest that long-term 217 
exposure to ciprofloxacin stress promotes reduced susceptibility to gepotidacin. 218 
 219 
Discussion 220 
In this work, we have primarily focused on studying the evolution of reduced susceptibility to 221 
gepotidacin in Klebsiella pneumoniae. As gepotidacin shows excellent potency against Gram-222 
negative bacteria(16, 17, 42), it could offer a last resort drug to treat multidrug-resistant Klebsiella 223 
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 9 
infections. However, we have demonstrated that two specific mutations in the genes encoding 224 
gepotidacin’s targets can provide a drastically reduced susceptibility in multiple enterobacterial 225 
species(21) (see also Table 1). These two mutations (GyrA D82N and ParC D79N) overlap with the 226 
predicted binding sites of the drug and show extreme synergism. By abolishing indispensable drug-227 
target interactions, they confer an over 2000-fold reduction in susceptibility, but individually they have 228 
only limited effects on susceptibility to gepotidacin. Alarmingly, the double-mutant K. pneumoniae 229 
strain is as virulent as the wild-type in a mouse infection model, suggesting that these mutations might 230 
have clinical significance. Indeed, Neisseria gonorrhoeae strains with reduced susceptibility to 231 
gepotidacin were isolated in a human clinical phase 2b trial carried a ParC D86N mutation(36) that 232 
corresponds to the homologous ParC D79N mutation in E. coli. 233 
According to what we term the “stepping-stone” hypothesis, prolonged clinical deployment of 234 
certain antibiotics may select for variants with an elevated potential to evolve resistance to new 235 
antimicrobial agents. For example, in Staphylococcus aureus the genetic alteration responsible for 236 
methicillin-resistance had emerged due to the selective pressure of first-generation beta-lactams, 237 
such as penicillin, years before methicillin was first applied in clinical practice(43). Hierarchical 238 
resistance-acquisition is also predominant during the evolution of resistance to fluoroquinolone 239 
antibiotics(44, 45). Furthermore, the byproducts of drug degradation were also shown to promote 240 
resistance development against clinically applied antibacterials(46).  241 
 To investigate the feasibility of the “stepping-stone” hypothesis, here we have focused on 242 
ciprofloxacin, a widely employed and well-characterized fluoroquinolone antibiotic(47). Similarly to 243 
gepotidacin, mutations in GyrA and ParC contribute to resistance to ciprofloxacin. Strikingly, 244 
mutations kinked to reduced susceptibility to gepotidacin (i.e., GyrA D82N, ParC D79N) increase 245 
resistance to ciprofloxacin and have been detected in clinical isolates of ciprofloxacin-resistant 246 
bacteria, including strains of N. gonorrhoeae, Streptococcus sp., and S. enterica. Therefore, these 247 
isolates are expected to require only one extra mutational step to develop a reduced susceptibility to 248 
gepotidacin.  249 
 The “stepping-stone” hypothesis may have general implications. For example, 250 
zoliflodacin (ETX0914), a novel bacterial topoisomerase inhibitor has just completed a human phase 251 
2 clinical trial(48). It shows promising activity against multidrug-resistant infections, including N. 252 
gonorrhoeae(49). However, in this species mutations in GyrB have been reported to confer 253 
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 10 
zoliflodacin-resistance(50), and one of these zoliflodacin-resistant mutants (D429N) has already been 254 
detected in clinical populations(51). As the homologous GyrB mutation (D426N) in E. coli confers 255 
resistance to fluoroquinolones(21), fluoroquinolone agents might have incidentally selected for 256 
reduced susceptibility to zoliflodacin as well. Consistent with this hypothesis, naturally occurring 257 
zoliflodacin-resistant variants were also found to be highly resistant to fluoroquinolones(51).  258 
In summary, our work demonstrates that despite a balanced in vivo targeting of multiple 259 
proteins, high-level resistance can rapidly emerge to antibiotics when the drug molecule’s inhibitory 260 
effect depends merely on interactions with a few, indispensable amino acids. It is an open issue 261 
whether this conclusion holds for a drug that inhibits two completely novel targets. Moreover, based 262 
on adaptive laboratory evolution and clinical data, we propose that target gene mutations conferring 263 
resistance to fluoroquinolones can facilitate resistance evolution to novel topoisomerase-targeting 264 
antimicrobials, including gepotidacin. Therefore, existing resistant bacteria could serve as an 265 
immediate source of novel resistance mechanisms. As a more general concept, our work indicates 266 
that even drugs executing a balanced multi-targeting of bacterial proteins are prone to resistance, and 267 
multi-targeting itself does not preclude the appearance of high-level resistance to antimicrobials. 268 
Regarding that a quarter of the antibiotics currently under clinical development target bacterial 269 
topoisomerases(52), further research is warranted to test this scenario.  270 
  271 
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Materials and Methods 272 
Media and antibiotics 273 
For general growth of bacteria and electrocompetent cell preparation, Lysogeny-Broth-Lennox (LB), 274 
medium was used (10 g tryptone, 5 g yeast extract, 5 g sodium chloride per 1 l of water). For cell 275 
recovery after electroporation, we applied Terrific Broth (TB) (24 g yeast extract, 12 g tryptone, 9.4 g 276 
K2HPO4, and 2 g KH2PO4 per 1 l of water). For antimicrobial susceptibility tests and the selection of 277 
resistant variants, cation-adjusted Mueller Hinton II Broth (MHBII) was used. To prepare MHBII broth, 278 
22 g of MHBII powder (Becton Dickinson and Co.) was dissolved in 1 l of water (3 g beef extract, 17.5 279 
g acid hydrolysate of casein and 1.5 g starch). MHBII agar was prepared by the addition of 14 g Bacto 280 
agar to 1 l bacterial MHBII broth. Bacterial media were sterilized by autoclaving 15 min at 121 °C. To 281 
distinguish lacZ knockout strains and wild-type strains, sterile solutions of X-gal (5-bromo-4-chloro-3-282 
indolyl-β-D-galactopyranoside) and IPTG (isopropyl β-D-1-thiogalactopyranoside) were added to the 283 
MHBII agar medium after autoclaving. Final X-gal and IPTG concentration in the medium were 40 284 
mg/l and 0.2 μM, respectively. Antibiotics and chemicals were ordered from Sigma-Aldrich (ampicillin, 285 
kanamycin, chloramphenicol; X-gal, IPTG), from Fluka Analytical (ciprofloxacin), and 286 
MedChemExpress (gepotidacin). 287 
 288 
Oligonucleotides 289 
Sequences of all synthetic DNA oligonucleotides (oligos) are listed in 290 
Supplementary file 1. Oligonucleotides were synthesized at the Nucleic Acid Synthesis Laboratory of 291 
the Biological Research Centre of the Hungarian Academy of Sciences. Soft-randomized DIvERGE 292 
oligos were manufactured according to a previously described soft-randomization protocol(21). PCR 293 
primers were purified with standard desalting, while mutagenic oligos were purified with high-294 
performance liquid chromatography (HPLC). Lyophilized oligos were dissolved in 1× Tris-EDTA (TE) 295 
buffer, pH 8 (Integrated DNA Technologies) at a final concentration of 100 μM. DIvERGE oligos were 296 
dissolved in 0.5× TE buffer at a final concentration of 500 μM. Dissolved oligos were stored at -20 °C. 297 
 298 
Homology model building 299 
Crystal structure of Staphylococcus aureus in complex with compound GSK945237 (PDB code: 300 
5NPP,(1) resolution of 2.22 Å) was chosen as a template to build a homology model of Escherichia 301 
 o
n
 July 23, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 12 
coli DNA Gyrase using Prime from the Schrödinger package(2, 3). GSK945237 is also a member of 302 
novel bacterial topoisomerase inhibitors (NBTI) therefore its binding position can serve as a template 303 
in our study. The homology model of Topoisomerase IV of Escherichia coli was created by using the 304 
X-ray structure of Klebsiella pneumoniae in complex with levofloxacin (PDB code: 5EIX(8)b, 305 
resolution of 3.35 Å) as a template. In the case of DNA Gyrase the DNA chain and the ligand 306 
GSK945237 (with both binding poses) were directly transferred from the template PDB structure 307 
5NPP. Since the DNA binding of the two enzyme shows high similarity, the DNA chain and the ligand 308 
was also transferred from 5NPP to the homology model of Topoisomerase IV after fitting the 309 
backbone atoms of the two proteins. In both cases the protein DNA contacts were checked and 310 
corrected separately using local conformation search and minimization. 311 
 312 
Computational docking of gepotidacin  313 
We docked gepotidacin (ChemSpider ID: 34982930) into the DNA gyrase and topoisomerase IV 314 
homology models using Glide from the Schrödinger package(53). The protonation state of gepotidacin 315 
was selected as the main species obtained from pKa calculation using the calculator plugin of Marvin 316 
program(54). For Glide docking we used OPLS3 force field(55) and the standard precision procedure 317 
with flexible ligand geometries and enhanced conformational sampling. Based on the high similarity of 318 
the mode-of-action of GSK945237 and gepotidacin(42), we picked the docking pose of gepotidacin 319 
that was most similar to the binding pose of GSK945237 in 5NPP structure. This procedure was 320 
repeated for the other docking-pose of GSK945237, as well. Finally, the binding site (defined as 321 
residues closer than 5 Å to the ligand) geometry together with the docked ligand was optimized. We 322 
followed the same steps in the case of both homology models.  323 
 324 
Molecular dynamics simulations of gepotidacin bound DNA-gyrase and DNA-topoisomerase IV 325 
complexes 326 
To perform molecular dynamics-based binding mode analysis for gepotidacin at both of its targets, we 327 
first parametrized the complex of formed by gepotidacin-DNA- and its corresponding target (DNA 328 
gyrase and topoisomerase IV, respectively). For parametrization, we used OPLS3 force field(55). 329 
Next, this system was solvated using the SPC (simple point charge)  explicit water model(56) within 330 
an orthorhombic box 10 Å apart. On the course of simulations, NaCl in 0.15 M final concentration was 331 
 o
n
 July 23, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 13 
used to mimic the physiological conditions. 100 ns molecular dynamics calculations were carried out 332 
on these systems at constant volume and temperature (NVT) using the Desmond molecular dynamics 333 
code
79
. Snapshots of these simulations were used as a conformational ensemble in mutation-induced 334 
binding free energy change calculations. 335 
 336 
Estimation of mutation-induced binding free energy changes 337 
Asparagine-mutation induced changes of the binding affinity (ΔΔGB) of gepotidacin at GyrA D82, and 338 
ParC D79 positions were calculated as the difference of their binding free energy in the mutated and 339 
wild-type enzyme (ΔΔGB= ΔGB
MUT
 -ΔGB
WT
). This affinity change was estimated by using Residue 340 
Scanning module of Bioluminate package(58) and was based on molecular mechanics-generalized 341 
Born surface area (MM-GBSA) approximation
21
. Specifically, we estimated the binding free energy of 342 
a ligand (∆𝐺) by using the single trajectory approach(59) in which a single molecular dynamics 343 
simulation of the protein-ligand complex is completed first and sample geometries are collected from 344 
the trajectory to represent the possible binding conformations. ∆𝐺 is calculated for every single 345 
geometry as 
 346 
∆𝐺 = 𝐺𝑃𝐿 − 𝐺𝑃 − 𝐺𝐿, 
where 𝐺𝑃𝐿, 𝐺𝑃 and 𝐺𝐿  are the energy of the protein ligand complex, protein and ligand, respectively. 347 
These energy values are calculated as 348 
𝐺 = 𝐺𝑀𝑀 + 𝐺𝑆𝑜𝑙𝑣, 
where 𝐺𝑀𝑀  is the calculated molecular mechanics energy for the force field applied, and 𝐺𝑆𝑜𝑙𝑣 is the 349 
solvation energy in the generalized Born approximation. Different variations of this method are widely 350 
used in large scale drug design studies
81–83
 as it accurately predicts mutational effects in drug-protein 351 
interaction analyses with a manageable computational demand (see e.g. references(63, 64)). In our 352 
study,  MM-GBSA calculations were carried out with the thermal_mmgbsa.py script Schrödinger 353 
package(58) from 100, evenly spaced structures from the second 50 ns of our previously performed 354 
molecular-dynamics simulation between the wild-type enzyme (DNA gyrase and topoisomerase IV) 355 
and gepotidacin. 356 
 357 
Plasmid construction  358 
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To perform ssDNA recombineering and DIvERGE in K. pneumoniae ATCC 10031, we generated a 359 
novel version of pORTMAGE, termed pORTMAGE311B. This plasmid possesses a tightly regulated, 360 
XylS-Pm regulator/promoter-based λ Beta and E. coli MutL E32K co-expression system. On, 361 
pORTMAGE the expression of MutL E32K of E. coli abolishes methyl-directed mismatch repair 362 
(MMR) during the time-period of oligonucleotide incorporation into the bacterial genome(65). 363 
pORTMAGE311B  ensured functionality at 37 °C and the rapid inducibility of λ Beta and E. coli MutL 364 
E32K by the addition of 1 mM m-Toluic-acid as an inducer. The temporal co-expression of λ Beta and 365 
MutL E32K also limits off-target mutagenic effects on the course of genome editing. Construction of 366 
pORTMAGE311B was performed by introducing the coding sequence of the dominant E. coli 367 
mutL(E32K) allele to the pSEVA258beta plasmid(66). To this aim, mutL(E32K) was PCR amplified 368 
from pORTMAGE2(65) using primers RBE32KF and XE32KR. The PCR product was then purified 369 
and digested with BamHI and XbaI. Next, the resulted fragment was cloned downstream of beta 370 
within pSEVA258beta. Finally, the successful assembly of the plasmid was verified by PCR and 371 
confirmed by capillary sequencing. pORTMAGE311B was also deposited to Addgene (Addgene 372 
Number 120418). 373 
 374 
DIvERGE in Klebsiella pneumoniae 375 
DIvERGE in Klebsiella pneumoniae ATCC 10031 was carried out according to a previously described 376 
DIvERGE workflow(21), with minor modifications. Briefly, K. pneuomoniae cells carrying 377 
pORTMAGE311B plasmid were inoculated into 2 ml LB medium + 50 μg/ml kanamycin and were 378 
grown at 37 °C, 250 rpm overnight. From this starter culture, 500 µl stationary phase culture was 379 
inoculated into 50 ml LB medium + 50 μg/ml kanamycin, and grown at 37 °C under continuous 380 
shaking at 250 rpm. Induction was initiated at OD600 = 0.4 by adding 50 μl 1 M m-Toluic-acid (Sigma-381 
Aldrich, dissolved in 96% ethyl-alcohol). Induction was performed for 30 minutes at 37 °C. After 382 
induction, cells were cooled on ice for 15 minutes. Next, cells were washed 3-times with 50 ml sterile, 383 
ice-cold, ultra-pure distilled water. Finally, the cell pellet was resuspended in 800 μl sterile ultra-pure 384 
distilled water and kept on ice until electroporation.  385 
To perform DIvERGE, and separately, the saturation mutagenesis of GyrA D82 and ParC D79, the 386 
corresponding gyrA, and parC-targeting oligos were equimolarly mixed at a final concentration of 500 387 
μM and 2 μl of this oligo-mixture was added to 40 µl electrocompetent cell in 10 parallels. Following 388 
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the electroporation of each sample, the 10 parallel samples were pooled together, and immediately 389 
after electroporation cells were suspended in 50 ml TB to allow for cell recovery. After a 1-hour 390 
recovery period at 37 °C, 250 rpm, an additional 50 ml LB medium along with 50 μg/ml (final cc.) 391 
kanamycin was added. Next, cells were grown at 37 °C, 250 rpm for 24 hours. To select clones with 392 
reduced susceptibility to gepotidacin from this DIvERGE library, 500 µl cell library was spread to 6 393 
µg/ml gepotidacin-containing MHBII agar plates and plates were incubated at 37 °C for 48 hours. 394 
Finally, 10 randomly selected colonies were analyzed by capillary sequencing (oligos: KPGA1F, 395 
KPGA1R and KPPC1F, KPPC1R) from both antibiotic-selected cell libraries. 396 
 397 
Engineering mutations associated with reduced susceptibility to gepotidacin in Escherichia 398 
coli 399 
To assess the phenotype of mutations associated with reduced susceptibility to gepotidacin, we 400 
individually reconstructed both GyrA D82N and ParC D79N mutations in E. coli K-12 MG1655. We 401 
utilized a previously described CRISPR-MAGE protocol to integrate mutations and counter select 402 
against the wild-type genotype(67, 68). Briefly, cell-containing pORTMAGE2 (Addgene #72677) were 403 
transformed with pCas9 (Addgene #42876)  and were grown in LB + 100 µg/ml ampicillin +  20 µg/ml 404 
chloramphenicol broth at 30 
o
C. Next, pCRISPR plasmids (Addgene #42875) were constructed with 405 
crRNA sequences targeting the wild-type gyrA and parC loci in the vicinity of D82 and D79 according 406 
to a previously described protocol (oligos: ECGACRF1, ECGACRR1, and ECPCCRF1, ECPCCRR1, 407 
respectively). Following plasmid-construction, correct clones were identified by capillary sequencing. 408 
To integrate GyrA D82N and ParC D79N mutations into the chromosome of E. coli, induced 409 
pORTMAGE2 and pCas9-carrying cells were prepared and made electrocompetent. Next, 410 
simultaneously, 100 ng of the corresponding pCRISPR plasmid and 200 pmole of oligonucleotide 411 
(MGYRA82N or MPARC79N) per 40 μl electrocompetent cells were electroporated. Cell were allowed 412 
to recover in 1 ml TB media and grown in 5 ml LB + 100 µg/ml ampicillin +  20 µg/ml chloramphenicol 413 
broth at 30 °C overnight and then spread to LB + 50 µg/ml kanamycin + 20 µg/ml chloramphenicol 414 
agar plates. Finally, the presence of the correct mutations was identified by capillary sequencing of 415 
the oligo-targets (oligos: 25922Ga1, 25922Ga3, and 25922Pc1, 25922Pc3). 416 
 417 
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Engineering isogenic Klebsiella and Salmonella strains carrying mutations associated with 418 
reduced susceptibility to gepotidacin and fluoroquinolones 419 
To investigate mutational effects on antibiotic susceptibility and growth phenotypes, mutations and 420 
mutation combinations linked to reduced susceptibility to gepotidacin and ciprofloxacin were 421 
reconstructed in K. pneumoniae ATCC 10031 and in Salmonella enterica ssp. enterica serovar 422 
Typhimurium. To this aim, specific point mutations (see Supplementary file 1) were inserted into the 423 
chromosome of K. pneumoniae by pORTMAGE-recombineering(21, 65). Briefly, pORTMAGE-424 
recombineering was performed using pORTMAGE311B (Addgene #120418). 1 μl of 100 μM of the 425 
corresponding oligos or oligo-mixtures were used for ssDNA-recombineering in appropriate 426 
combinations to create mutations linked to reduced susceptibility to gepotidacin and ciprofloxacin. 427 
Following recombineering, cells were allowed to grow overnight in TB medium at 37°C, 250 rpm. 428 
Next, variants carrying ciprofloxacin resistance-conferring mutations were selected on LB + 100 ng/ml 429 
ciprofloxacin agar plates, while mutants carrying the GyrA D82N; ParC D79N mutation-combination 430 
were selected on MHBII + 6 μg/ml gepotidacin agar plates. Cells carrying individual mutations 431 
assocated with reduced susceptibility to gepotidacin were plated onto LB + 50 μg/ml kanamycin agar 432 
plates. To obtain individual colonies, cultures from each recombineering populations were diluted, and 433 
appropriate dilutions were spread to agar plates. Plates were incubated at 37 °C, and individual 434 
colonies were genotyped by allele-specific PCR (using oligos KPA82ASF, KPA82ASR, and 435 
KPC79ASF, KPC79ASR). Finally, positive clones were confirmed by capillary sequencing of the oligo-436 
target region. The reconstruction of the clinically prevalent GyrA D82 mutation in combination with a 437 
ParC D79N mutation in Salmonella enterica ssp. enterica serovar Typhimurium LT2 were conducted 438 
similarly to the reconstruction of specific mutations in K. pneumoniae. Briefly, pORTMAGE311B-439 
containing, induced S. enterica cells were made electrocompetent and transformed with 1 µl of 440 
SE_GA_D82N and SE_PC_D79N oligos that integrated the corresponding GyrA D82N and ParC 441 
D79N mutations into the bacterial chromosome. Next, mutants were selected on MHBII + 6 μg/ml 442 
gepotidacin agar plates at 37 °C. Finally, the presence of the two mutations was identified and 443 
validated by capillary sequencing using SEGAF1, SEGAR1, and SEPCF1, SEPCR1 oligos. 444 
 445 
Adaptive laboratory evolution of ciprofloxacin resistance 446 
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Adaptive laboratory evolution experiments followed an established protocol for automated laboratory 447 
evolution(69) and aimed to maximize the drug-resistance increment during a fixed time period. At 448 
each transfer step, 10
7
 bacterial cells were transferred to a new culture and adaptation were 449 
performed by passaging 6 independent populations of Klebsiella pneumoniae ATCC 10031 wild-type, 450 
Escherichia coli K-12 MG1655 wild-type, and Escherichia coli K-12 MG1655 ΔmutS in the presence 451 
of increasing ciprofloxacin concentrations. Experiments were conducted in 96-well plates, in MHBII 452 
medium, by utilizing a checker board layout to minimize and to monitor cross-contamination. These 453 
96-well deep-well plates (0.5 ml, polypropylene, V-bottom) were covered with sandwich covers 454 
(Enzyscreen BV) to ensure an optimal oxygen exchange rate and limit evaporation and were shaken 455 
at 150 rpm at 37 ˚C. Twenty μl of each evolving culture was parallelly transferred into four 456 
independent wells containing 350 μl fresh medium and an increasing concentration of gepotidacin and 457 
ciprofloxacin (i.e., 0.5×, 1×, 1.5×, and 2.5× the concentration of the previous concentration step). 458 
Following cell transfer, each culture was allowed to grow for 48 h. At each transfer, cell growth was 459 
monitored by measuring the optical density at 600 nm (OD600) (Biotek Synergy 2). Only populations 460 
with (i) vigorous growth (i.e., OD600 > 0.25) and (ii) the highest drug concentration were selected for 461 
further evolution. Accordingly, only one of the four populations was retained for each independently 462 
evolving strain. This protocol was designed to avoid population extinction and to ensure that 463 
populations with the highest level of resistance were propagated further during evolution. Samples 464 
from each transfer were frozen in 15% dimethyl-sulfoxide (DMSO) at −80 ˚C for further analysis. 465 
Adaptation of an individual population was terminated when the antibiotic concentration in the given 466 
well would have exceeded 200 μg/ml after the transfer. Cells from these, highly-drug resistant 467 
populations were frozen after the addition of 15% dimethyl-sulfoxide (DMSO) and were kept at −80 468 
˚C. Following adaptation, cells from each final population were spread onto MHBII agar plates and 469 
individual colonies were isolated.  470 
 471 
Whole genome sequencing of adapted lines 472 
Following adaptive laboratory evolution of ciprofloxacin resistance in K. pneuomoniae ATCC 10031 473 
and E. coli K-12 MG1655, single colonies from three adapted lines were subjected to whole genome 474 
sequencing on Illumina HiSeq 4000. Prior to sequencing, gDNA was isolated from each adapted line 475 
and the corresponding wild-type strain by using GeneElute (Sigma Aldrich) gDNA isolation kit 476 
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according to the manufacturer’s instructions. To perform DNA sequencing, sequencing libraries were 477 
constructed from the gDNAs by fragmenting samples to a mean fragment length of 300 bp. Next, 478 
sequencing libraries were prepared by using a TruSeq DNA PCR-Free Library Prep Kit (Illumina). 479 
Finally, sequencing libraries were sequenced on a single sequencing lane of Illumina HiSeq 4000 480 
using a HiSeq 3000/4000 SBS Kit (300 cycles, FC-410-1003, Illumina) to generate 2 × 150 bp paired-481 
end reads. Following sequencing, in order to determine the variants and to annotate the mutations, 482 
we mapped sequencing reads to their corresponding reference genomes with the mem subcommand 483 
of bwa 0.7.12-r1039 (Burrows-Wheeler Aligner(70)). The SNPs and INDELs were called with 484 
VarScan(71) v2.3.9 with the following parameters: min-reads2=4, min-coverage=30, min-var-freq=0.1, 485 
min-freq-for-hom=0.6, min-avg-qual=20, strand-filter=0. Only variants with prevalence higher than 486 
60% were voted as mutations. Following variant calling, mutations were also manually inspected 487 
within the aligned reads, and adapted lines that become hypermutators (i.e. that are accumulated 488 
more than 55 mutations in a single lineage) were excluded from further analysis. Finally, the 489 
annotation of each mutation with genomic features was performed with the intersect subcommand of 490 
bedtools v2.25.0. 491 
 492 
In vitro growth-rate measurements 493 
We measured the growth phenotype of bacterial variants by assessing their growth at 37 ̊C in MHBII 494 
medium. To measure growth, we inoculated 5×10
4 
cells from early stationary phase cultures 495 
(prepared in MHBII medium) into 100 μl of MHBII medium in a 96 well microtiter plate and monitored 496 
growth for 24 h. Bacterial growth was measure as the 600 nm optical density (OD600) of cultures at a 497 
given timepoint. OD600 measurements were carried out every 5 minutes using BioTek Synergy 2 498 
microplate reader while bacterial cultures were grown at 37 ̊C under continuous, variable intensity 499 
shaking. Each bacterial variant and their corresponding wild-types were measured in two consecutive 500 
experiments, with 12 replicates in each subsequent tests (24 biological replicates in total). Finally, 501 
growth rates were calculated from the obtained growth curves according to a previously described 502 
procedure(72, 73). 503 
 504 
Competition-based fitness measurements 505 
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Competition assay-based fitness measurements were carried out by competing mutant strains against 506 
their corresponding wild-type strain carrying a lacZ knockout mutation. The lacZ knockout strain was 507 
constructed by integrating a premature stop codon in place the 23
rd
 amino acid of LacZ with a 508 
previously reported pORTMAGE protocol(65). Briefly, heat-induced pORTMAGE3 (Addgene #72678) 509 
containing K. pneuomoniae ATCC 10031 cells were electroporated with KpLacZW23* oligonucleotide 510 
(2.5 nM final concentration). Following oligo-integration into the bacterial chromosome, lacZ(-) 511 
variants were identified by plating cells out to X-gal + IPTG-containing MHBII agar plates at 512 
appropriate dilution to form single colonies, where knockout mutants formed white colonies and could 513 
be easily distinguished from the dark blue colonies of the wild-type containing a functional β-514 
galactosidase gene. Each competition experiment started by inoculating early stationary phase 515 
cultures in a 99:1, as mutant to wild-type ratio, into 10 ml MHBII medium at 1:1000-fold dilution and 516 
incubating each culture at 37 °C for 24 h under a constant agitation of 250 rpm. These cultures were 517 
then serially transferred into 10 ml fresh MHBII medium in a 1:1000 dilution in every 24 hours for 3 518 
subsequent transfers. To analyze the composition of each population, cultures were plated onto X-gal 519 
+ IPTG supplemented MHBII agar plates (in 145×20 mm Petri dishes, Greiner Bio-One Ltd) at 520 
appropriate dilutions to obtain approximately 1000 colonies per each plate. Plates were then 521 
incubated at 37 °C overnight. The ratio of the mutant (lacZ proficient, blue) and the wild-type (lacZ 522 
deficient, white) at each given time point was determined from the number of blue and white colonies 523 
on X-Gal + IPTG agar plates. Importantly, prior experiments showed that lacZ deficient K. 524 
pneumoniae cells suffer no competitive disadvantage compared to their corresponding wild-type 525 
strain. Competition experiments were performed in five replicates. Finally, selection coefficients were 526 
estimated as the slope of the change in ratio, as defined in the following equation: 527 
ln[x1(t)/x2(t)]  =  ln[x1(0)/x2(0)]  +  st 
where s is the selection coefficient, t is time or number of generations, x1 and x2 are the ratio of the 528 
two strains at a given time point(74). 529 
 530 
Prevalence of mutations associated with reduced susceptibility to gepotidacin in sequence 531 
databases 532 
In order to investigate if genotypes GyrA D82 and ParC D79N exist in bacteria, we downloaded all 533 
DNA sequences from NCBI nucleotide database (ftp://ftp.ncbi.nlm.nih.gov/blast/db/nt.??.tar.gz) using 534 
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wget 1.17.1 on 9 Oct 2018. We performed the BLAST search with tBLASTn 2.231(75) (build Jan 7 535 
2016) on the downloaded full nucleotide database as subject and GyrA and ParC as query. Protein 536 
sequences of GyrA (P0AES4) and ParC (P0AFI2) were downloaded from UniProt. To perform 537 
BLAST, the database was fragmented and the BLAST search was carried out on these smaller 538 
datasets (with argument max_target_seqs = 20000). Finally, separately obtained results were 539 
merged. Finally, for each sequence the taxonomy of the source bacteria was assigned with 540 
blastdbcmd (version 2.2.31). 541 
 542 
Mouse thigh infection models 543 
Drug-resistant K. pneumoniae is frequently responsible for wound and systemic infections, therefore, 544 
we benchmarked in vivo effects of reduced susceptibility gepotidacin in a murine thigh wound 545 
infection model(29, 30). Specifically, we examined wound colonization for representative gepotidacin 546 
and ciprofloxacin-resistant mutants of K. pneumoniae ATCC 10031 and compared to that of the wild-547 
type. Murine thigh infections were performed according to a previously established protocol(30, 76). 548 
Bacterial inoculums were prepared by inoculating single bacterial colonies into 5 ml of MHBII broth 549 
and were incubated at 37 °C for 16 hours under constant agitation (250 rpm).  Next, ½ volume of 50 550 
volume/volume% glycerol:water mixture was added to each culture and 550 µl of these cell 551 
suspensions were frozen at -80 °C. Before inoculation, cell suspensions were allowed to thaw at room 552 
temperature for 15 minutes. As test animals, groups of 5 female specific-pathogen-free ICR (CD-1) 553 
mice weighing 22 ± 2 g were used. Animals were immunosuppressed by two intraperitoneal injections 554 
of cyclophosphamide, the first at 150 mg/kg 4 days before infection (day –4) and the second at 100 555 
mg/kg 1 day before infection (day –1).  On day 0, animals were inoculated intramuscularly into the 556 
right thigh with 10
6
 CFU/mouse of the corresponding pathogenic mutant (0.1 ml culture/thigh). After 557 
26 hours inoculation, animals were humanely euthanized with CO2 asphyxiation and then the muscle 558 
of the right thigh was harvested from each test animal.  The removed muscle was homogenized in 3 559 
ml of phosphate-buffered saline, pH 7.4, with a polytron homogenizer. Finally, 0.1 mls of these 560 
homogenates were used for serial 10-fold dilutions and plated onto LB agar for colony count (CFU/g) 561 
determination. 562 
 All aspects of this work including housing, experimentation, and animal disposal were 563 
performed in general accordance with the Guide for the Care and Use of laboratory animals (National 564 
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Academy Press, Washington, DC, 2011). All experiments were performed under ABSL2 conditions in 565 
the AAALAC(American Association for Accreditation of Laboratory Animal Care)-accredited vivarium 566 
of Eurofins Pharmacology Discovery Services Taiwan, Ltd. with the oversight of veterinarians to 567 
assure compliance with IACUC regulations and the humane treatment of laboratory animals. 568 
 569 
Minimum Inhibitory Concentration measurements 570 
Minimum Inhibitory Concentrations (MICs) were determined using a standard serial broth 571 
microdilution technique according to the EUCAST guidelines(77) (ISO 20776-1:2006, Part 1). Briefly, 572 
bacterial strains were inoculated from frozen cultures onto MHBII agar plates and were grown 573 
overnight at 37 °C. Next, independent colonies from each strain were inoculated into 1 ml MHBII 574 
medium and were propagated at 37 °C, 250 rpm overnight. To perform MIC assays, 12-step serial 575 
dilutions using 2-fold dilution-steps of the given antibiotic were generated in 96-well microtiter plates 576 
(Sarstedt 96-well microtest plate with lid, flat base). Antibiotics were diluted in 100 μl of MHBII 577 
medium. Following dilutions, each well was seeded with an inoculum of 5×10
4
 bacterial cells. Each 578 
measurements were performed at least in 3 parallel replicates. Also, to avoid possible edge effects at 579 
the edge of the microwell plate, side-rows (A and H) contained only medium without bacterial cells. 580 
Following inoculations, plates were covered with lids and wrapped in polyethylene plastic bags to 581 
minimize evaporation but allow for aerobic O2 transfer. Plates were incubated at 37 °C under 582 
continuous shaking at 150 rpm for 18 hours in an INFORS HT shaker. After incubation, OD600 of each 583 
well on the microwell plate was measured using a Biotek Synergy 2 microplate reader. MIC was 584 
defined as the antibiotic concentration which inhibited the growth of the bacterial culture, i.e., the drug 585 
concentration where the average OD600 increment of the three replicates was below 0.05. 586 
 587 
 588 
  589 
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 854 
Figure 1. Binding site analysis of gepotidacin based on directed evolution and molecular 855 
modelling. (A) Gepotidacin, a novel triazaacenaphthylene antibiotic candidate inhibits DNA gyrase 856 
and topoisomerase IV in Gram-negative bacteria. (B-C) Ribbon representation of E. coli’s DNA 857 
gyrase- and topoisomerase IV in complex with gepotidacin, based on molecular dynamics 858 
simulations. Inlet shows the close-up view of gepotidacin (yellow) and its interacting residues (red) in 859 
a stick model. DNA is shown in magenta and blue. (D) The workflow of in vivo directed evolution of 860 
reduced susceptibility to gepotidacin in K. pneumoniae ATCC 10031. 861 
 Gepotidacin MIC Ciprofloxacin MIC 
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(µg/ml) (µg/ml) 
E. coli K-12 MG1655 wild-type 0.25 0.016 
E. coli K-12 MG1655 GyrA D82N 0.5 0.125 
E. coli K-12 MG1655 ParC D79N 0.5 0.016 
E. coli K-12 MG1655 GyrA D82N; ParC D79N >256 0.25 
K. pneumoniae ssp. pneumoniae ATCC 10031 
wild-type 
0.063 0.004 
K. pneumoniae ssp. pneumoniae ATCC 10031 
GyrA D82N 
0.5 0.063 
K. pneumoniae ssp. pneumoniae ATCC 10031 
ParC D79N 
0.125 0.008 
K. pneumoniae ssp. pneumoniae ATCC 10031 
GyrA D82N; ParC D79N 
256 0.063 
 862 
Table 1. Gepotidacin and ciprofloxacin minimal inhibitory concentration of single-step 863 
mutations and their combination in Escherichia coli K-12 MG1655 and Klebsiella pneumoniae 864 
ATCC 10031. Growth inhibition was determined by optical density (OD600) measurements of the 865 
bacterial culture after 18 h incubation in the presence of the corresponding drug concentration, 866 
according to the EUCAST guidelines(77). Results presented here as the mean of 9 independent 867 
replicates respectively. 868 
  869 
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(A) 870 
 871 
(B)  872 
 873 
  874 
Figure 2. Fitness cost and virulence of bacteria with reduced susceptibility to gepotidacin.  (A) 875 
In vitro competition between mutant and wild-type Klbsiella pneumoniae. Isogenic mutants of 876 
Klebsiella pneumoniae ATCC 10031 carrying either a mutation combination conferring to reduced 877 
susceptibility to gepotidacin or its single-step constituents (red), or clinically-occurring fluoroquinolone 878 
resistance-associated mutations (blue) competed against the wild-type strain. In competition assays, 879 
a competitive index <0 indicates that the wild-type population outcompetes the mutant population, and 880 
conversely, a competition index >0 indicates that the mutant population outcompetes the wild-type 881 
population. Error bars indicate standard deviation (SD) based on five biological replicates. (B) 882 
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Virulence of Klebsiella pneumoniae mutants and the wild-type strain in a murine thigh infection model. 883 
Bacterial burden in infected thigh tissues after 26 hours of infection caused by wild-type Klebsiella 884 
pneumoniae ATCC 10031 (black) or isogenic mutants carrying either mutations causing reduced 885 
susceptibility to gepotidacin or its single-step constituents (red), or clinically-occurring mutations 886 
associated with fluoroquinolone resistance (blue).  The bacterial burden was assayed in Colony 887 
Forming Units (CFU)/g of tissue (n = 5 animals per data point, see Methods for details). No mutants 888 
were found to display a significant difference in virulence compared to the wild-type strain (t-test, P 889 
>0.05 for all pairwise comparisons). 890 
  891 
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(A) 892 
 893 
(B) 894 
 895 
 896 
Figure 3. Adaptive laboratory evolution of Klebsiella pneumoniae and Escherichia coli under 897 
ciprofloxacin stress. (A) Figure shows the antibiotic concentrations at which K. pneumoniae ATCC 898 
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10031, as well as E. coli K-12 MG1655 wild-type and mutS hypermutator strains were able to grow 899 
under increasing ciprofloxacin stress as a function of time (number of cell generations). Dashed line 900 
represents the clinical breakpoint of ciprofloxacin resistance according to EUCAST(41). (B) Relative 901 
resistance level of the evolved lines against ciprofloxacin (grey bars) and gepotidacin (yellow bars) 902 
compared to the wild type at the end of the adaptive laboratory evolution. Asterisk (*) indicates that 903 
the evolved line was subjected to whole genome sequence analysis to uncover mutational processes 904 
behind the reduced susceptibility. 905 
 906 
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